Substance / Medication

Finafloxacin

Overview

Active Ingredient
finafloxacin
RxNorm CUI
1598641

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Taubert Max, Chiesa Joseph, Lückermann Mark et al. · Antimicrob Agents Chemother · 2017
PMID: 28784673RCTFull text (PMC)
Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
Patel Heena, Andresen Arne, Vente Andreas et al. · Antimicrob Agents Chemother · 2011
PMID: 21709093RCTFull text (PMC)
High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.
Lee Jung Won, Kim Nayoung, Nam Ryoung Hee et al. · Antimicrob Agents Chemother · 2015
PMID: 26416863ObservationalFull text (PMC)
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.
Kocsis Béla, Gulyás Dániel, Szabó Dóra · Antibiotics (Basel) · 2021
PMID: 34943718ReviewFull text (PMC)
Activity of Finafloxacin against Panels of Respiratory Pathogens.
Harding Sarah V, Barnes Kay B, Hawser Stephen et al. · Antibiotics (Basel) · 2023
PMID: 37508192OtherFull text (PMC)
Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis andSpecies.
Kong Yingying, Li Chao, Li Gangfeng et al. · Microbiol Spectr · 2022
PMID: 35532225OtherFull text (PMC)
Efficacy of finafloxacin in a murine model of inhalational glanders.
Barnes Kay B, Bayliss Marc, Davies Carwyn et al. · Front Microbiol · 2022
PMID: 36504783OtherFull text (PMC)
Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever.
Hartley M Gill, Norville Isobel H, Richards Mark I et al. · Front Microbiol · 2021
PMID: 34917048OtherFull text (PMC)
Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection.
Barnes Kay B, Richards Mark I, Laws Thomas R et al. · Antimicrob Agents Chemother · 2021
PMID: 33753342PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Finafloxacin (substance)
SNOMED CT
708794002
UMLS CUI
C2825286
RxNorm CUI
1598641

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.